Sunday, April 21, 2019

TransMed Systems Rebrands as Inteliquet

BWW News Desk
April 15, 2019

TransMed Systems, Inc., a leading provider of technology, insights and services for clinical research and translational medicine announced today it has rebranded the company as Inteliquet. The name represents the concept of bringing intelligence through clarity to dramatically improve the way clinical trials and research are conducted for all stakeholders—most importantly, the patient. Its solutions optimize the clinical development process and many aspects of clinical research. Its team of experts work toward ensuring no patient goes without access to a clinical trial and that promising new therapies get to market as quickly as possible.

“The way we prove new medical discoveries—the next breakthrough drug or treatment—is through clinical trials,” said Carla Balch, CEO of Inteliquet. “But nearly half of trials do not meet recruitment goals in part because not enough patients know about them or participate in them. Every day that patients are not offered access to appropriate clinical trials is a missed opportunity to advance science and improve health outcomes, especially for critical diseases such as cancer. We need to change the process for everyone. The potential for new therapies demands it. Our vision is to knock down barriers and reduce the time involved to find the right patients for the right clinical trials.”

Inteliquet’s software platform, vast sets of patient data, and expert services work together to create a significantly improved, automated process to find eligible patients faster, identify patients that could be eligible in the near future, and find the right sites for specific trials based on available patient populations. Inteliquet also helps life sciences and contract research organizations conduct more effective clinical development planning, including trial feasibility, and increases visibility of trials for clinicians. In addition, Inteliquet’s consortium has established itself as the fastest growing oncology data-sharing consortium with more than 520 oncologists participating.

“Inteliquet’s technology provides the clearest, most complete view of data to improve the way clinical trials and research work for all of us,” said Balch. “This clarity helps fast-track the connection between a new therapy and a patient who needs it. Getting these therapies to patients faster benefits everyone. We are working toward the day when all stakeholders have a single source of truth and everyone has access to therapies that extend or save lives the moment they need them.”

The relaunch of the company as Inteliquet follows a period of rapid growth, including Balch taking on the role of CEO in 2018 and an expanded leadership team with significant industry expertise. Balch previously served as President of NantCare, an oncology clinical trial and technology company. As president and CEO of Altos Solutions, she led its sale to Flatiron Health, a Google-Ventures backed organization recently acquired by Roche for $2 billion. In November, the company also named Jeff Edenfield, MD, as its first Chief Medical Officer. Dr. Edenfield is a treating oncologist and Clinical Associate Professor at University of South Carolina’s School of Medicine.

About Inteliquet

Inteliquet is a leading provider of intelligent technology, insights and expertise that help dramatically to reduce the barriers and time involved in designing and conducting clinical trials and research, from feasibility and site selection to patient screening and matching. We harness vast sets of oncology and patient data to bring a new level of clarity to the process and to accelerate new scientific discoveries. Our team, partners, customers, and Scientific Advisory Board are passionate about ensuring that every patient—regardless of race, geography, age, sex, economic status, or stage of disease—has access to promising therapies as soon as they become available to help improve the care they, and future generations, receive. Find out more at www.inteliquet.com, and follow us on Twitter, LinkedIn and Facebook.

SOURCE: BUSINESS WIRE. ©2015 Business Wire

Comments

Registration Login
Registration Login
Registration Login
Registration